Advancing precision drug through innovative chemistry and advanced molecular technologies.
Integrated CDMO services spanning discovery, process development, custom synthesis and commercial manufacturing.
Delivering reliable CDMO solutions for innovative therapeutics worldwide.
CHEMOS致力于打造以产品为牵引、合成技术驱动的CDMO品牌，为全球制药及生物技术公司提供有机合成、工艺开发、定制合成和项目放大服务。我们聚焦于药物递送系统（LNP、GalNAc）、生物偶联化学（ADC Linker）、放射性药物化学（DOTA、NOTA）、靶向蛋白降解（PROTAC、分子胶）及功能性分子砌块等高壁垒领域，依托研发团队、先进合成技术、分析平台和生产基地，为客户提供从路线开发到放大生产支持的系统化解决方案。
了解我们最新发展与行业洞察
FDA announced on July 16, 2026 that Lipfendra (enlicitide) was approved to be used with diet and exercise to reduce LDL-C in adults with high cholesterol or heterozygous familial hypercholesterolemia. FDA also states that Lipfendra is a tablet taken by mouth once daily and is the first oral therapy that blocks PCSK9.
更多The key correction is that the ACS Organic Process Research & Development paper describes LUNA18 (paluratide) through a liquid-phase peptide synthesis process, not a simple SPPS plus three-fragment route. The paper’s abstract says the authors departed from conventional solid-phase peptide synthesis and developed an LPPS process for an N-alkyl-rich cyclic undecapeptide KRAS inhibitor.
更多
The reported inclisiran architecture illustrates why an siRNA conjugate cannot be reduced to a sequence plus a targeting ligand. Descriptions of that architecture place a triantennary N-acetylgalactosamine (GalNAc) unit at the sense-strand terminus, combine 2'-fluoro and 2'-O-methyl ribose substitutions with terminal phosphorothioate linkages, and rely on the antisense strand for RNA-induced silencing complex (RISC) loading. Each element addresses a different constraint: cell uptake, nuclease exposure, strand handling, or intracellular recognition.
无论您处于早期研发、路线探索、工艺开发还是项目放大阶段，CHEMOS始终以有机合成能力、研发团队和生产基地为支撑，为您提供高效、可靠的定制合成解决方案。
